Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "irbesartan amlodipine irbesartan Hypertension" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about irbesartan amlodipine irbesartan Hypertension for you to read. Along with our medical data and news we also list irbesartan amlodipine irbesartan Hypertension Clinical Trials, which are updated daily. BioPortfolio also has a large database of irbesartan amlodipine irbesartan Hypertension Companies for you to search.
* Says its unit receives ANDA approval for its irbesartan and hydrochlorothiazide tablets from U.S Food and Drug Administration
Teva has received the approval from the US Food and Drug Administration (FDA) for its generic hypertension treatments Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) and Azor (amlodipine and olmesartan medoxomil). The Israeli company’s Azor generic has already launched in the US, while the Tribenzor generic has entered final pre-launch stages. read more
After nearly five years of follow-up, adults with hypertension who received chlorthalidone had a 21 percent lower risk of hip and pelvic fractures compared with those who received lisinopril or amlodipine, according to a post hoc analysis of a randomized trial.
* Alembic Pharmaceuticals Limited receives ANDA approval for Telmisartan and Amlodipine tablets Source text: [Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 18, 2016, title " Alembic Pharmaceutical...
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension
Teva Pharmaceutical Industries' generic version of Tribenzor tablets, or olmesartan medoxomil, amlodipine and hydrochlorothia -More-
Ajanta Pharma has launched its amlodipine and olmesartan medoxomil tablets in the US market after receiving approval from the -More-
Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office: Tokyo; President and CEO: Yoshihiko Hatanaka, hereafter “Astellas”) announced today that the companies have newly launched “Micatrio® Combination Tablets,” a combina...
Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office: Tokyo; President and CEO: Yoshihiko Hatanaka, hereafter “Astellas”) announced that manufacturing and marketing approval for “Micatrio® Combination Tablets,” a combin...
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 74-year-old woman is evaluated during a routine examination. Her medical history is significant for hypertension and obesity. She is a former smoker, stopping 5 years ago. Medications are amlodipine, lisinopril, and aspirin. On physical examination, she is afebrile, blood pressure [...
Hypertension, more commonly known as high blood pressure, has increased significantly in children, paralleling the current childhood obesity epidemic. Although we know that adult hypertension can affect the brain, little research has been done on the cognitive effects of childhood hypertension. In a new study scheduled for publication in the Journal of Pediatrics, researchers found that hypertensi...
Antihypertensive Therapeutics in AsiaPacific Markets to 2021 Increasing Prevalence of Hypertension Drives Market Growth despite Weak PipelineSummaryHypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate CAGR of 1.2% to 561 million in 2021 in ...
MELBOURNE, Australia, 6 December 2016: Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced that it has completed recruitment of patients into Part A of its Phase 2 trial for DMX-200, an innovative new treatment chronic kidney disease that combi...
In a study of patients with hypertension, those with resistant hypertension--meaning that their blood pressure remained elevated despite concurrent use of three antihypertensive agents of different classes--had a higher rate of sleep apnea (9.6%) than those without resistant hypertension (7.2%).
• Data from 21 participants shows the therapy is well tolerated with an encouraging safety profile • Twenty seven percent (27%, 3/11) patients who have reached or passed the mid-point of the study have shown an approx. 50% reduction or greater in proteinuria over and above standard of care • Final data from Part A of the Phase 2 study is expected in 2H 2017 MELBOURNE, Austral...
In a study of patients with hypertension, those with resistant hypertension—meaning that their blood pressure remained elevated despite concurrent use of three antihypertensive agents of different classes—had a higher rate of sleep apnea (9.6%) than those without resistant hypertension (7.2%). Resistant hypertensive patients with sleep apnea had an increased risk of ischemic heart events and c...
• Path to drug registration in USA of DMX-200 in patients with chronic kidney disease (CKD) confirmed • Path to the near term milestone of filing IND for the first US study (PK study) – no apparent roadblocks or extra costs identified at this stage • DMX-200 to be treated as an adjunct therapy rather than a combination therapy – resulting in a much smaller pivotal t...